Zydus Lifesciences Ltd - 532321 - Board Resolution-Buyback
Board Resolution-Buyback12-02-2024
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper cutting with regard to publication of extracts of unaudited financial results for the quarter / nine months ended on December 31, 2023 in Financial Express on February 10, 2024.10-02-2024
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Investor Call Link09-02-2024
Q3FY24 Quarterly & 9MFY24 Result Announced for Zydus Lifesciences Ltd.
Pharmaceuticals company Zydus Lifesciences announced Q3FY24 & 9MFY24 results: Consolidated Q3FY24: - Revenue from operations stood at Rs 45,052 million, marking a 6% increase from the previous year. - EBITDA for the quarter was reported at Rs 11,024 million, up 15% YoY, with an EBITDA margin of 24.5%, an increase of 200 basis points (bps) YoY. - Research & Development (R&D;) investment was Rs 3,146 million, representing 7.0% of revenues. - The Net Profit for the quarter noted a significant rise of 27% YoY reaching Rs 7,896 million. - Organic capital expenditure (Capex) for the quarter amounted to Rs 2,137 million. Consolidated 9MFY24: - Revenue from operations reached Rs 140,136 million, up by 15% compared to the last year. - EBITDA for 9MFY24 stood at Rs 37,538 million indicating a 44% YoY increase. EBITDA margin was 26.8%, improving by 550 bps over the previous year. - Research & Development (R&D;) investment over nine months was Rs 9,580 million, equivalent to 6.8% of revenues. - Net Profit surged by 61% YoY to Rs 26,772 million. - Organic Capex for the nine months was Rs 6,502 million. Business Segment Performance – Q3FY24 - India Geography: Reported revenue of Rs 18,247 million with an 11% YoY growth. - US Formulations: Registered revenue of Rs 18,427 million, experiencing a slight decline of 4% YoY. - Emerging Markets & Europe Formulations: Noted revenue of Rs 4,937 million, a substantial growth of 31% YoY. - API Business: Revenue was at Rs 1,431 million, down by 24% YoY. - Alliances & Others: Reported a sharp revenue increase of 59% YoY, reaching Rs 395 million. Share Buyback - Zydus Lifesciences announced a share buyback worth Rs 6000 million, representing 0.59% of total outstanding equity shares for Rs 1,005 per share, which is a 25% premium over the closing price as of February 8, 2024. Dr. Sharvil Patel, Managing Director of Zydus Lifesciences, said, "We are pleased with our Q3FY24 performance, particularly with a strong recovery in the domestic formulations business and a resilient US base business. Importantly, our journey of sustained profitability improvement continues and we hope to sustain the same. We are optimistic about our growth prospects driven by a differentiated portfolio in the US, and the continued performance of key brands, well supported by a robust execution engine. We remain on track to end the fiscal year 2024 with a healthy double-digit revenue growth and expect to improve EBITDA margins to 27% plus levels." Result PDF09-02-2024
Zydus Lifesciences Ltd - 532321 - Update On Buyback
Promoters intention to participate in buyback09-02-2024
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation09-02-2024
Zydus Lifesciences Ltd - 532321 - Record Date Of Buyback: February 23, 2024
Record date of buyback: February 23, 202409-02-2024